Severe coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus is frequently characterized by pulmonary inflammation \[[@CR1]\]. Life-threatening "cytokine storms" involving the release of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1, IL-8, and MCP-1) may contribute to the rapid systemic organ failure observed in select critically ill COVID-19 patients \[[@CR1]\]. However, this storm is not a self-limiting, singular event. SARS-CoV-2 causes massive cell death and cellular debris that activates inflammasomes \[[@CR2]\], which in turn trigger a macrophage-derived "eicosanoid storm", a surge of pro-inflammatory bioactive lipid mediators, such as prostaglandins and leukotrienes, that fuels local inflammation \[[@CR3]--[@CR5]\]. A paradigm shift in the inflammation field is that the resolution of inflammation is an active biochemical process \[[@CR5]\], implying that hyper-inflammation may result from a deficit in resolution.

In contrast to classic anti-inflammatory agents, endogenous pro-resolution lipids can terminate the inflammatory response by promoting the clearance of cellular debris. Specialized pro-resolving mediators (SPMs), including resolvins, lipoxins, and protectins, are bioactive lipid autacoids that mediate endogenous resolution by stimulating macrophage phagocytosis of cellular debris and countering the release of pro-inflammatory cytokines/chemokines \[[@CR5]\]. Importantly, loss of inflammation resolution mechanisms plays a role in sustaining pathologic inflammation \[[@CR5]\]. Endogenous resolution processes have been identified in the termination of infectious diseases \[[@CR5]\], including influenza \[[@CR6]--[@CR8]\], and could thus be harnessed for averting dysregulated inflammation and associated mortality in COVID-19. SPMs promote anti-viral B lymphocytic activity in influenza \[[@CR7]\], suggesting they may be a promising therapy for COVID-19. SPM precursors including 17-hydroxydocosahexaenoic acid (17-HDHA) have also been identified as potentially promising vaccine adjuvants as they protect against primary influenza infection and promote adaptive immunity \[[@CR7], [@CR8]\]. Thus, the use of SPMs or their precursors in combination with COVID-19 vaccines may be a novel and effective therapeutic approach.

The resolution of inflammation is also stimulated by another pathway involving arachidonic acid--derived epoxyeicosatrienoic acids (EETs). These mediators promote clearance of cellular debris and activate anti-inflammatory programs to inhibit several key pro-inflammatory cytokines \[[@CR9], [@CR10]\]. EETs and other epoxy fatty acids specifically promote production of SPMs, such as lipoxins, by shifting arachidonic acid metabolism to favor inflammation resolution \[[@CR11]\]. As EETs are rapidly metabolized by soluble epoxide hydrolase (sEH), administration of sEH inhibitors (sEHIs) can stabilize EET levels, prevent lung inflammation, and improve lung function in animal models, making them an attractive potential therapeutic strategy for COVID-19. Both SPMs and sEHIs downregulate the transcription regulator NF-κB \[[@CR5], [@CR11]\], the center of eicosanoid-induced cytokine storms, which promotes the induction of pro-inflammatory cytokines and prostaglandin synthesis via cyclooxygenase (COX). Combined pharmacological abrogation of COX-2 and sEH activity also prevents cytokine and eicosanoid storms via debris clearance mechanisms \[[@CR4]\], offering another promising therapeutic intervention.

Targeting individual pro-inflammatory cytokines may not be sufficient to prevent COVID-19 progression. Importantly, SPMs terminate self-sustaining inflammatory processes, such as those induced by COVID-19, by broadly inhibiting pro-inflammatory cytokine production and promoting a return to tissue homeostasis \[[@CR5], [@CR7], [@CR8]\]. In contrast to some anti-inflammatory agents, which may be contraindicated in COVID-19 patients, SPMs and sEHIs act at significantly lower doses and are not immunosuppressive \[[@CR5], [@CR11]\]. Moreover, conventional anti-inflammatory agents such as NSAIDs and COX-2 inhibitors, while limiting the eicosanoid storm, may be "resolution toxic" as they indiscriminately inhibit eicosanoid pathways that produce resolution mediators and thereby prevent active resolution \[[@CR5]\]. Inhibiting resolution mediator production may potentially facilitate COVID-19-induced tissue injury and progression of infection. As demonstrated in many inflammatory disease models, selectively promoting endogenous inflammation resolution mechanisms clears inflammatory exudates more effectively and promotes a return to tissue homeostasis compared with classic anti-inflammatory agents \[[@CR5]--[@CR11]\].

Most COVID-19 clinical trials focus on "anti-viral" and "anti-inflammatory" strategies. In contrast, stimulation of inflammation resolution is a novel host-focused alternative to complement current therapies. The loss of active resolution mechanisms \[[@CR5]\] and dysregulation of SPMs and EETs in sustained pathological inflammation and lung diseases present a new opportunity for the management of COVID-19. Pro-resolving mediators, as well as sEH blockade, may resolve the potentially fatal cytokine storm and severe pulmonary inflammation in COVID-19 patients (see Fig. [1](#Fig1){ref-type="fig"}). Importantly, both SPMs and EETs have also been shown to attenuate pathologic thrombosis and promote clot removal, which is now recognized as a key pathology of COVID-19 infection \[[@CR12]--[@CR14]\]. SPMs including resolvins, lipoxins, and protectins, as well as sEHIs, are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 by complementing current anti-viral strategies via debris clearance and inflammatory cytokine suppression. Thus, activating endogenous resolution pathways may be a novel therapeutic approach to limit severe organ damage and improve outcomes in COVID-19 patients.Fig. 1Inflammation resolution in severe COVID-19 infection. The left alveolus demonstrates (1) viral-induced alveolar cell death and the accumulation of apoptotic and necrotic cellular debris. This debris elicits a pro-inflammatory response from macrophages (2), which in turn produce high quantities of eicosanoids generating an "eicosanoid storm". These eicosanoids subsequently stimulate the production of pro-inflammatory cytokines (3) by immune cells such as macrophages, generating a robust "cytokine storm" that in turn promotes further leukocytosis and immune cell infiltrates (4). This robust inflammatory response to viral infection promotes hyaline membrane formation (5) and subsequent acute respiratory distress syndrome. Tissue levels of SPMs and EETs are decreased in this robust inflammatory setting. The right alveolus demonstrates COVID-19 infection in the setting of active inflammation resolution mechanisms, as is the case in mild infection or potentially following treatment with SPMs or sEH inhibition to increase EETs. EETs promote the generation of SPMs from arachidonic acid and omega-3 fatty acids. SPMs (1) stimulate macrophage phagocytosis and efferocytosis, (2) decrease pro-inflammatory cytokine production, (3) inhibit leukocytosis and thereby decrease the inflammatory infiltrate, and (4) may stimulate the adaptive immune response and the production of anti-SARS-CoV-2 antibodies
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